Supreme Court: Foreign Companies’ Head Office Expenses in India are Capped under Section 44C  ||  SC Directs Trial Courts to Systematically Catalogue Witnesses and Evidence in Criminal Judgments  ||  SC Calls For Sensitising Future Generations on Equality in Marriage to Combat Dowry Practices  ||  SC: Separate Suits Against Confirmed Auction Sales are Barred; Remedy Available under Sec 47  ||  NCLT Mumbai: Oppression Claims Against Majority Shareholders Do not Justify Winding up a Company  ||  J&K&L HC Rules it Illegal and Inequitable to Deny Regularisation to a Daily Wager After 34 Years  ||  J&K&L High Court: Revisional Powers Must Be Used Within Reasonable Time; Merits Don’t Justify Delay  ||  Supreme Court: Compassionate Appointees Cannot Later Claim Entitlement to a Higher Post  ||  NCLAT New Delhi: Insolvency Pleas Cannot Be Admitted When Information Utility Records Show a Dispute  ||  NCLAT: Issuing Cheques For Another Entity’s Liabilities Does not Constitute Operational Debt    

Delhi HC Issues Notice in PIL Seeking Selling of Remdesivir by All Pharma Firms in Domestic Market - (04 May 2021)

CIVIL

Delhi High Court has issued notice to the Centre and various pharma majors asking them to respond to a Public Interest Litigation seeking that all drug firms involved in the making Remdesivir be allowed to sell it in the domestic market. The Court has issued the notice to the Health Ministry, Central Drugs Standard Control Organisation, Director General of Foreign Trade, and various pharma companies, like Cipla, Zydus, and Cadila, seeking their stand on the issue.

Tags : DELHI HIGH COURT   SELLING OF REMDESIVIR  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved